?Project1 Our previous data have shown that the aged microenvironment drives resistance to targeted therapy, and may impact response to immunotherapyas well. Tumor cells undergo metabolic reprogramming in order to acquire resistance to BRAF/MEK inhibitors. We have found that one of the contributing factors to this resistance may be lipids. Aged or stressed fibroblasts secrete lipids, whichare takenup by melanoma cells, promoting their ability to invade, and resist targeted therapy. These stromally-induced changes can also affect immune cells. Dendritic cells (DC) are required for the initiation and maintenance of immune responses and lipid accumulation in DC decreases their ability to act as antigen presenting cells. Myeloid derivedsuppressorcells(MDSCs)playamajorroleinregulationofantitumorimmunity.Thesecellsthriveon lipidmetabolismandtheyaccumulateanduseoxidizedlipidstoaugmenttheirabilitytosuppresstheimmune microenvironment.Wehaveimplicatedfattyacid(FA)transporterprotein2(FATP2)inlipidaccumulationby bothtumorcellsandPMN-MDSC,suggestingacomplexcrosstalkbetweenmultiplecomponentsoftheTME. We propose to identify the mechanism and subsequent functional consequences of lipid accumulation in tumorcellsandMDSCs. WewillevaluatetheeffectoftherapeutictargetingoflipidaccumulationinMDSCs on the generation of immune responses in melanoma models, and on tumor cell fate and response to targetedtherapy.

Public Health Relevance

?Project1 The prognosis for melanoma patients over the age of 60 is markedly lower than younger patients, and therapy is less effective. We have discovered that aged fibroblasts secrete lipids that affect melanoma cell response to therapy, as well as the activity of myeloid derived suppressor cells. In this project, we will elucidate the mechanisms by which this occurs, and determine the implications of lipid accumulation in the agedtumormicroenvironmentfortherapyofmelanoma.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Wistar Institute
United States
Zip Code
Hammerlindl, Heinz; Ravindran Menon, Dinoop; Hammerlindl, Sabrina et al. (2018) Acetylsalicylic Acid Governs the Effect of Sorafenib in RAS-Mutant Cancers. Clin Cancer Res 24:1090-1102
Ecker, Brett L; Kaur, Amanpreet; Douglass, Stephen M et al. (2018) Age-Related Changes in HAPLN1 Increase Lymphatic Permeability and Affect Routes of Melanoma Metastasis. Cancer Discov :
CaƱadas, Israel; Thummalapalli, Rohit; Kim, Jong Wook et al. (2018) Tumor innate immunity primed by specific interferon-stimulated endogenous retroviruses. Nat Med 24:1143-1150
Grasso, Michael; Estrada, Michelle A; Berrios, Kiara N et al. (2018) N-(7-Cyano-6-(4-fluoro-3-(2-(3-(trifluoromethyl)phenyl)acetamido)phenoxy)benzo[d]thiazol-2-yl)cyclopropanecarboxamide (TAK632) Promotes Inhibition of BRAF through the Induction of Inhibited Dimers. J Med Chem 61:5034-5046
Noguera-Ortega, Estela; Amaravadi, Ravi K (2018) Autophagy in the Tumor or in the Host: Which Plays a Greater Supportive Role? Cancer Discov 8:266-268
Jenkins, Russell W; Aref, Amir R; Lizotte, Patrick H et al. (2018) Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov 8:196-215
Emptage, Ryan P; Lemmon, Mark A; Ferguson, Kathryn M et al. (2018) Structural Basis for MARK1 Kinase Autoinhibition by Its KA1 Domain. Structure 26:1137-1143.e3
Barnoud, Thibaut; Budina-Kolomets, Anna; Basu, Subhasree et al. (2018) Tailoring Chemotherapy for the African-Centric S47 Variant of TP53. Cancer Res 78:5694-5705
Liu, Shujing; Zhang, Gao; Guo, Jianping et al. (2018) Loss of Phd2 cooperates with BRAFV600E to drive melanomagenesis. Nat Commun 9:5426
Pathria, Gaurav; Scott, David A; Feng, Yongmei et al. (2018) Targeting the Warburg effect via LDHA inhibition engages ATF4 signaling for cancer cell survival. EMBO J 37:

Showing the most recent 10 out of 144 publications